Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20371116 | 0.91 | KMT2A (0.44) | MDM2KMT2AMDM4TP53BMP1 | |
| SCHEMBL14113024 | 0.88 | KMT2A (0.41) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL26231259 | 0.87 | KMT2A (0.43) | MDM2KMT2AMDM4TP53BMP1 | |
| SCHEMBL3423921 | 0.83 | KMT2A (0.46) | MDM2KMT2AMDM4TP53BMP1 | |
| SCHEMBL889833 | 0.83 | KMT2A (0.46) | MDM2KMT2AMDM4TP53BMP1 | |
| SCHEMBL8843737 | 0.83 | KMT2A (0.52) | MDM2KMT2AMDM4TP53CASP3 | |
| SCHEMBL7801461 | 0.82 | KMT2A (0.52) | MDM2KMT2AMDM4TP53GAA | |
| SCHEMBL20371136 | 0.82 | MDM2 (0.46) | MDM2KMT2AMDM4TP53CASP3 | |
| SCHEMBL25280271 | 0.81 | MDM2 (0.55) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL31749819 | 0.81 | MDM2 (0.55) | MDM2MDM4TP53CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778613-B2 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778613-B2 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778613-B2 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2157429-A2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | Reverse Proteomics Research Institute Co., Ltd (JP) | 2010-02-24 | — | — | EP | disclosed |
| EP-2110393-A1 | Affinity resin | Reverse Proteomics Research Institute Co., Ltd (JP) | 2009-10-21 | — | — | EP | disclosed |
| US-20070167594-A1 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167594-A1 | Affinity resin | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1674486-A1 | AFFINITY RESIN | Reverse Proteomics Research Institute Co., Ltd (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167594-A1 | Affinity resin | FCGR2A, FCGR1A, CD14 | MDM2 2601/4885KMT2A 887/4885MDM4 1328/4885 |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | MDM2 1955/4885KMT2A 3769/4885MDM4 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.